Ironwood Raises Full-Year 2026 Guidance After Third-Quarter Results
Ironwood said U.S. LINZESS net sales year to date surpassed total 2025 sales, citing sales growth as it raised guidance for the second consecutive quarter.
Story updates
12:05:42 PM UTC
SquawkNews
Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 - $1.25 billion, rep
Ironwood reported third-quarter 2026 results and raised full-year 2026 guidance for the second consecutive quarter, citing LINZESS U.S. net sales growth. Year-to-date U.S. LINZESS net sales surpassed total 2025 sales.Material DetailsContext by AI AnalystThis is a further upward guidance revision fo…